Protective efficacy of Chlorophytum borivilianum root extract against murine visceral leishmaniasis by immunomodulating the host responses.
Antibody responses
Cytokine responses
DTH responses
Histopathology
Parasite load
Phytochemical constituents
Journal
Journal of Ayurveda and integrative medicine
ISSN: 0975-9476
Titre abrégé: J Ayurveda Integr Med
Pays: United States
ID NLM: 101551404
Informations de publication
Date de publication:
Historique:
received:
06
04
2017
revised:
26
08
2017
accepted:
30
10
2017
pubmed:
19
8
2018
medline:
19
8
2018
entrez:
19
8
2018
Statut:
ppublish
Résumé
The available drugs for treating visceral leishmaniasis are limited. Moreover, the disease is associated with suppression of immune function. Therefore, therapies with effective immunomodulatory agents are needed which can decrease parasitic burden and enhance adaptive immunity. The present study was planned to evaluate the antileishmanial efficacy of crude ethanolic extract of roots of Chlorophytum borivilianum (CBREE) against murine visceral leishmaniasis through immunomodulation. The in vitro studies were carried out to check leishmanicidal activity against promastigote form and cytotoxicity against HeLa cells. The parasite load in liver smears, immunological and biochemical changes induced by 500 and 1000 mg/kg b.wt. of CBREE were assessed on 1, 7, 14 and 21 post treatment days in infected and treated BALB/c mice. CBREE showed inhibitory effect on growth of promastigotes with IC50 of 28.25 μg/mL and negligible cytotoxicity. The extract was toxicologically safe in BALB/c mice when administered orally with 5 g/kg b.wt. of extract. A significant reduction in parasite load was observed along with active immunomodulation through enhanced Th1 type of immune responses and suppressed Th2 type of immune responses. The treatment with both doses showed no toxic effect as evidenced by normal liver and kidney function tests and normal histological observations of liver and kidney. Therefore, it should be further explored for its active components in pursuit of the new effective antileishmanial agents in the plant kingdom.
Sections du résumé
BACKGROUND
BACKGROUND
The available drugs for treating visceral leishmaniasis are limited. Moreover, the disease is associated with suppression of immune function. Therefore, therapies with effective immunomodulatory agents are needed which can decrease parasitic burden and enhance adaptive immunity.
OBJECTIVES
OBJECTIVE
The present study was planned to evaluate the antileishmanial efficacy of crude ethanolic extract of roots of Chlorophytum borivilianum (CBREE) against murine visceral leishmaniasis through immunomodulation.
MATERIALS AND METHODS
METHODS
The in vitro studies were carried out to check leishmanicidal activity against promastigote form and cytotoxicity against HeLa cells. The parasite load in liver smears, immunological and biochemical changes induced by 500 and 1000 mg/kg b.wt. of CBREE were assessed on 1, 7, 14 and 21 post treatment days in infected and treated BALB/c mice.
RESULTS
RESULTS
CBREE showed inhibitory effect on growth of promastigotes with IC50 of 28.25 μg/mL and negligible cytotoxicity. The extract was toxicologically safe in BALB/c mice when administered orally with 5 g/kg b.wt. of extract. A significant reduction in parasite load was observed along with active immunomodulation through enhanced Th1 type of immune responses and suppressed Th2 type of immune responses.
CONCLUSION
CONCLUSIONS
The treatment with both doses showed no toxic effect as evidenced by normal liver and kidney function tests and normal histological observations of liver and kidney. Therefore, it should be further explored for its active components in pursuit of the new effective antileishmanial agents in the plant kingdom.
Identifiants
pubmed: 30120057
pii: S0975-9476(17)30196-1
doi: 10.1016/j.jaim.2017.10.009
pmc: PMC7125388
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53-61Informations de copyright
Copyright © 2017 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Published by Elsevier B.V. All rights reserved.
Références
Exp Parasitol. 2015 Jun;153:45-54
pubmed: 25747203
J Vector Borne Dis. 2008 Dec;45(4):255-72
pubmed: 19248652
J Glob Infect Dis. 2010 May;2(2):151-8
pubmed: 20606971
J Nat Prod. 2015 Mar 27;78(3):552-6
pubmed: 25629555
Trans R Soc Trop Med Hyg. 2006 Mar;100(3):264-9
pubmed: 16289167
Arch Toxicol. 1983 Dec;54(4):275-87
pubmed: 6667118
J Nat Prod. 2015 Apr 24;78(4):653-7
pubmed: 25835647
Front Plant Sci. 2015 Aug 25;6:655
pubmed: 26379683
PLoS Negl Trop Dis. 2012;6(5):e1629
pubmed: 22563510
J Ethnopharmacol. 2013 Nov 25;150(2):421-41
pubmed: 24045177
Clin Exp Immunol. 1977 Oct;30(1):119-29
pubmed: 606433
Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):597-8
pubmed: 15307436
Curr Pharm Biotechnol. 2009 Nov;10(7):650-66
pubmed: 19751181
Evid Based Complement Alternat Med. 2007 Dec;4(4):419-23
pubmed: 18227908
Eur J Med Chem. 2012 Dec;58:613-23
pubmed: 23178961
Int J Parasitol Drugs Drug Resist. 2013 Dec 05;4(1):20-7
pubmed: 24596665
J Nat Prod. 2009 Jan;72(1):177-81
pubmed: 19128156
Afr J Tradit Complement Altern Med. 2007 Feb 16;4(3):313-8
pubmed: 20161895
Drug Resist Updat. 2006 Feb-Apr;9(1-2):26-39
pubmed: 16814199
Drug Chem Toxicol. 2010 Apr;33(2):173-82
pubmed: 20307144
Nat Protoc. 2006;1(3):1458-61
pubmed: 17406435
Bioorg Med Chem. 2014 Jan 1;22(1):18-45
pubmed: 24355247
J Nat Prod. 2009 Jun;72(6):1069-74
pubmed: 19489596
J Nat Prod. 2010 Jan;73(1):60-6
pubmed: 20030365
Vaccine. 2010 May 21;28(23):4002-12
pubmed: 20093205
Anc Sci Life. 2004 Jul;24(1):30-7
pubmed: 22557148
Pharmacognosy Res. 2010 Nov;2(6):343-9
pubmed: 21713136
Parasitol Res. 2014 Jan;113(1):333-9
pubmed: 24173812
Evid Based Complement Alternat Med. 2011;2011:598521
pubmed: 21792363
Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):350-4
pubmed: 15228258
Free Radic Res. 2009;43(11):1101-10
pubmed: 19669998
Front Immunol. 2012 Aug 14;3:251
pubmed: 22912637
Adv Appl Microbiol. 2013;82:155-84
pubmed: 23415155
Exp Parasitol. 2012 Mar;130(3):223-31
pubmed: 22227102
Exp Parasitol. 2015 Apr-May;151-152:84-95
pubmed: 25655407